Aicar 50mg By Dragon Pharma

AICAR 50mg — Acadesine Nucleoside AMPK Activator by Dragon Pharma

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, Acadesine) is Dragon Pharma's formulation of the nucleoside analogue AMPK activator at 50mg per vial — a compound banned by WADA in 2011 precisely because its use in elite endurance sport was documented and its performance-enhancing mechanism is real. AICAR is not a peptide, not a SARM, and not a growth factor — it is a nucleoside analogue that enters cells and is phosphorylated to ZMP, which directly activates AMPK (AMP-activated protein kinase), the master cellular energy sensor that drives endurance adaptation, fat oxidation and mitochondrial biogenesis.

Also searched as: AICAR 50mg, Acadesine, AICAR AMPK, AICAR endurance, Acadesine Dragon Pharma.

What AICAR Is — Nucleoside Analogue, Not a Peptide

AICAR's chemical class is important for understanding how it works:

• AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is a nucleoside analogue — a synthetic compound structurally related to adenosine, one of the four nucleoside building blocks of RNA and DNA
• It is not a peptide (no amino acid chain), not a steroid (no steroidal ring structure), not a SARM (no androgen receptor binding) and not a growth factor (no receptor for growth signalling)
• AICAR was originally developed as a cardioprotective agent for use during cardiac surgery — it was studied for its ability to protect heart tissue during ischemia (oxygen deprivation). Its AMPK-activating properties and metabolic effects were discovered as researchers explored its mechanism more deeply
• The compound gained attention in endurance sport when Bahr et al. and subsequent researchers demonstrated that AICAR administration in sedentary animals produced endurance adaptations similar to aerobic exercise training — without the training itself

The ZMP Mechanism — How AICAR Activates AMPK

The specific intracellular mechanism distinguishes AICAR from other AMPK activators:

• After injection, AICAR enters cells via adenosine transporters — the same membrane transporters that move adenosine across the cell membrane
• Inside the cell, AICAR is phosphorylated by adenosine kinase to form ZMP (5-aminoimidazole-4-carboxamide ribonucleotide monophosphate) — which accumulates intracellularly
• ZMP is a structural analogue of AMP (adenosine monophosphate) — it binds the AMP-sensing domain of AMPK and mimics the "low energy" signal that AMP itself sends when cellular energy charge is depleted (e.g. during intense exercise)
• This AMPK activation then triggers the full suite of downstream metabolic adaptations: increased fatty acid oxidation (more fat burned for energy), increased glucose uptake in muscle (GLUT-4 translocation), decreased gluconeogenesis in liver, mitochondrial biogenesis, and upregulation of genes involved in oxidative phosphorylation
• The key distinction from indirect AMPK activators: ZMP activates AMPK directly at the allosteric site — a more direct mechanism than compounds like metformin which activate AMPK indirectly through inhibition of Complex I of the mitochondrial electron transport chain

The WADA Ban — Why Elite Sport Banned AICAR in 2011

AICAR's anti-doping status reflects its documented real-world performance-enhancing use:

• WADA added AICAR (and GW501516/Cardarine) to the Prohibited List in 2011 under the category of "metabolic modulators" — a new category created specifically to address these non-hormonal performance-enhancing compounds
• The ban followed reports of AICAR use in professional cycling, where its endurance-enhancing effects without masking the hematological markers of EPO doping made it attractive to athletes wanting to avoid detection
• The documented competitive use provides a real-world validation of AICAR's endurance effects in trained humans — not just in sedentary rodents from laboratory studies
• AICAR is detectable in urine and blood tests through targeted metabolomic screening — its use in tested competition is not viable

The Landmark Animal Study — What Narkar et al. (Cell, 2008) Showed

The foundational AICAR exercise mimetic publication:

• Narkar et al. (Cell, 2008) — the same Salk Institute lab that investigated GW501516 — demonstrated that AICAR administration in sedentary mice increased running endurance by approximately 44% compared to controls, without any exercise training
• The endurance improvement was associated with increased expression of genes involved in fatty acid oxidation and mitochondrial biogenesis in skeletal muscle — confirming AMPK activation was driving transcriptional changes toward the trained phenotype
• The combination of AICAR + GW501516 (PPARδ agonist) produced an approximately 75% endurance improvement — demonstrating that AMPK and PPARδ pathways are synergistic, each amplifying the other's effects on oxidative metabolism genes

AICAR vs MOTS-c vs SLU-PP-332 — The AMPK Pathway Comparison

Three compounds in the Dragon Pharma range activate AMPK but through meaningfully different upstream mechanisms:

Effects and Benefits

• Direct AMPK activation via ZMP accumulation — the most pharmacologically direct AMPK activator available
• Endurance enhancement — approximately 44% improvement in sedentary animal models (Narkar et al.); documented use in elite human endurance sport
• Increased fatty acid oxidation — AMPK drives fat as the primary fuel source during sustained effort
• Mitochondrial biogenesis — AMPK activates PGC-1α, the master regulator of mitochondrial content
• Improved insulin sensitivity — AMPK drives GLUT-4 translocation in muscle independently of insulin
• No testosterone suppression — no PCT required

Dosage and Administration

At 50mg per vial, full-dose protocols use one vial daily — a significant cost per day of use. Pre-workout injection 30-60 minutes before training is common practice to align AMPK activation with the exercise window. Reconstitute with bacteriostatic water. Store refrigerated at 2-8°C after reconstitution for up to 28 days. Cycle length is not firmly established — AICAR does not cause receptor desensitisation like beta-2 agonists, so continuous use is pharmacologically viable, though cost considerations typically drive cycling.

Side Effects

• Hypoglycaemia risk — AMPK activation drives significant glucose uptake in muscle and reduces hepatic glucose output; in fasted or caloric-deficit states, blood glucose can drop meaningfully. Avoid combining with insulin or other hypoglycaemic agents
• Mild nausea — reported at higher doses; typically dose-dependent and transient
• No hormonal effects — no testosterone, estrogen or HPG axis interaction; no PCT required

Reconstitution and Storage

Reconstitute with bacteriostatic water — add slowly along the vial wall and swirl gently. Store reconstituted vial refrigerated at 2-8°C for up to 28 days. Never freeze.

Stacking and Related Compounds

• GW-501516 Cardarine — PPARδ agonist; the Narkar et al. (2008) paper demonstrated ~75% endurance improvement when combined with AICAR vs ~44% for AICAR alone — the two pathways are synergistic
• MOTS-c — activates AMPK via the folate cycle/AICAR accumulation pathway; complementary upstream AMPK activation to AICAR's direct ZMP mechanism
• SLU-PP-332 — ERR pan-agonist; activates mitochondrial biogenesis through ERRα/PGC-1α, a downstream convergence point shared with AMPK activation